A polygenic risk score (PRS) is a single number that estimates your genetic predisposition to a particular disease or trait, calculated by adding up the tiny effects of thousands, sometimes millions, of genetic variants scattered across your genome. Unlike tests for a single high-risk gene mutation, a PRS captures the cumulative weight of common variants that individually do almost nothing but collectively shift your odds in a meaningful direction. These scores are already being used in research to stratify risk for heart disease, several cancers, diabetes, and psychiatric conditions, and they are beginning to appear in clinical settings and consumer testing kits. But their accuracy varies enormously depending on who you are, what disease is being predicted, and how the score was built.
How a Polygenic Risk Score Is Built
The starting ingredient for any PRS is data from a genome-wide association study, or GWAS, which scans the DNA of a large population to find genetic variants statistically linked to a disease or trait. Each variant gets a weight reflecting how much it nudges risk up or down. Your PRS is then the sum of those weights across all the variants you carry. The concept is straightforward, but the methods for choosing which variants to include and how to weight them have become surprisingly sophisticated, ranging from simple thresholding approaches to Bayesian statistical models that attempt to account for the complex relationships between variants.1PubMed Central. Methodologies underpinning polygenic risk scores estimation: a comprehensive overview
The quality of a PRS depends heavily on the GWAS it is derived from. Larger studies with more participants produce more reliable variant weights, and the training population matters enormously for who the score works well for. A score trained primarily on data from people of European descent will perform differently when applied to someone of East Asian, African, or South Asian ancestry. The score itself is not a probability or a diagnosis. It is a relative ranking: it tells you where you fall on the spectrum of genetic risk compared to a reference population, not whether you will or will not get sick.
What These Scores Can Actually Predict
The predictive power of a PRS depends on the disease in question and how heritable it is. For coronary artery disease, PRS has become one of the more developed applications. Scores can identify people at elevated risk across multiple population cohorts and have even shown value in predicting responses to certain preventive therapies in post hoc analyses of clinical trials.2PubMed Central. Clinical utility of polygenic risk scores for coronary artery disease Researchers have proposed using the coronary artery disease PRS across the entire life course: to flag younger adults at elevated genetic risk before they develop high cholesterol or blood pressure, to sharpen mid-life risk estimates, and to guide treatment decisions after a diagnosis.3PubMed Central. Clinical applications of polygenic risk score for coronary artery disease through the life course
Cancer screening is another area generating interest. A study modeling the use of PRS alongside family history for breast cancer screening found that risk-stratified screening could yield roughly 29% more life-years gained and 18% fewer breast cancer deaths per 10,000 women screened compared to the standard age-based guideline, though it also produced more false positives and some additional overdiagnosis.4PubMed Central. Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History The idea is not to replace mammography but to personalize when it starts: a 40-year-old woman whose PRS puts her above a certain threshold may already face higher breast cancer odds than the average 50-year-old woman who qualifies for routine screening. One analysis estimated that using a breast cancer PRS as a first-stage screen in 100,000 women aged 40 would identify about 2,570 high-risk women for mammography, of whom roughly 108 would have breast cancer, but it would also miss over 1,400 cases among the women who screened below the threshold.5PubMed Central. Performance of polygenic risk scores in screening, prediction, and risk stratification: secondary analysis of data in the Polygenic Score Catalog That tradeoff between catching early cases and missing others is central to whether PRS-guided screening is worth adopting on a large scale.
Adding Genetics to Traditional Risk Tools
One of the strongest arguments for PRS is not that it replaces existing risk calculators but that it improves them. Traditional tools for predicting cardiovascular events use factors like your age, blood pressure, cholesterol, smoking status, and diabetes status. These work reasonably well for middle-aged and older adults, but they tend to underestimate risk in younger people who haven’t yet accumulated years of exposure to clinical risk factors. Genetics, by contrast, is fixed from birth, which means it can flag elevated risk decades earlier.
A study combining a PRS with a widely used clinical risk calculator found that about 10% of people who went on to develop coronary artery disease had been classified as low risk by the clinical tool alone but were correctly flagged as high risk by the integrated score. The improvement was largest in men aged 40 to 54, where reclassification improved by over 15%.6PubMed Central. Integrated Polygenic Tool Substantially Enhances Coronary Artery Disease Prediction Another study using data from NHS Health Checks in England reported that the standard clinical score identified about 26% of adults aged 40 to 54 who later had a major cardiovascular event, but combining it with PRS raised that figure to about 38%, a relative increase of nearly 48%.7European Heart Journal. Polygenic risk score adds to a clinical risk score in the prediction of cardiovascular disease in a clinical setting A separate analysis found that combining PRS with the pooled cohort equations improved overall model discrimination and produced a meaningful net reclassification improvement across risk categories.8PubMed Central. Polygenic risk score improves the accuracy of a clinical risk score for coronary artery disease
The pattern is consistent: PRS adds the most value in younger adults, where traditional risk scores are weakest. For a 65-year-old with high blood pressure, diabetes, and high cholesterol, the clinical picture already tells a clear story and PRS adds less. For a healthy 45-year-old with a clean lipid panel, PRS can surface hidden genetic risk that wouldn’t show up any other way.
The Ancestry Gap
The biggest scientific and ethical limitation of current PRS is that they work best for people of European descent and substantially worse for everyone else. This is not a flaw in the concept but a direct consequence of how the underlying research was conducted. The vast majority of GWAS data comes from participants of European ancestry, which means the variant weights baked into most PRS are tuned for that population. When applied to individuals of African, South Asian, East Asian, or Latin American descent, these scores are several times less accurate, which means they systematically benefit European-descent populations more than others.9PubMed Central. Clinical use of current polygenic risk scores may exacerbate health disparities
This is a problem that researchers are actively working to fix. Newer methods that incorporate GWAS data from multiple ancestral populations have shown significant improvements in PRS accuracy for non-European groups. One approach, evaluated across more than five million individuals of diverse ancestry involving 13 traits, demonstrated substantially better performance in non-European populations compared to simpler alternatives, with results comparable to much more computationally demanding methods.10Nature Genetics. A new method for multiancestry polygenic prediction improves performance across diverse populations But closing the gap fully will require much more diverse genetic data collection, and progress, while real, is still incomplete.
Where Polygenic Risk Scores Struggle
Psychiatric conditions have been a testing ground for PRS since the concept’s earliest days, but the results here are sobering. A critical appraisal of PRS across multiple diseases found that the diagnostic and prognostic performance of PRS alone is consistently low, in part because these scores capture only the heritable component of disease and ignore the substantial contributions of environment and lifestyle.11PubMed Central. Clinical utility of polygenic risk scores: a critical 2023 appraisal
Even within a single condition, PRS results can be surprisingly inconsistent. A study examining multiple PRS for schizophrenia, depression, alcohol use disorder, and type 2 diabetes found that less than half of individuals identified as high risk by one schizophrenia PRS were also identified as high risk by a different schizophrenia PRS. For depression and alcohol use disorder, the overlap was even lower, sometimes dropping below 10%. Sensitivity was moderate to good depending on the condition, but specificity was low across the board, meaning the scores generated a lot of false positives.12PubMed Central. Low Stability and Specificity of Polygenic Risk Scores for Major Psychiatric Disorders Limit their Clinical Utility When surveyed, most experts in psychiatric genetics agreed that PRS are not yet robust enough to assess individual susceptibility to schizophrenia, citing low predictive power and insufficient population diversity as the most significant obstacles.13PubMed Central. How do experts in psychiatric genetics view the clinical utility of polygenic risk scores for schizophrenia?
The instability problem matters for a practical reason: if your “high risk” label depends on which version of the PRS your doctor uses, the clinical value of that label is shaky. Until different scoring methods converge on more consistent results, using PRS alone to guide psychiatric treatment or screening is premature for most conditions.
Genetic Risk Changes with Age
One of the more counterintuitive findings about PRS is that their relative predictive strength is not constant across your lifetime. For multiple diseases, the relative risk associated with a high PRS is greatest in younger adults and diminishes with age. A study of prostate cancer PRS found significantly greater relative risks in men aged 30 to 55 compared with men aged 70 to 88, with the genetic relative risk decreasing roughly linearly from age 50 to 75.14PubMed Central. Polygenic risk for prostate cancer: Decreasing relative risk with age but little impact on absolute risk A broader investigation of age-dependent genetic risk across nine diseases, including hypertension, skin cancer, and heart disease, confirmed this pattern: genetic risk factors generally have their greatest relative impact on early disease, with a steady decline over time.15PLOS Genetics. The impact of age on genetic risk for common diseases
This does not mean your genetic risk disappears as you get older. It means that environmental and lifestyle factors accumulate with age, effectively diluting the relative contribution of genetics. A 45-year-old with a high coronary artery disease PRS stands out from the crowd more than a 75-year-old with the same score, because by 75, many people have developed high blood pressure and arterial plaque regardless of their genetic starting point. For Parkinson’s disease, a polygenic hazard score comparing the highest to the lowest risk decile produced a hazard ratio of about 3.8, and researchers used it to estimate genetically stratified risk at different ages.16PubMed Central. Genetic Stratification of Age-Dependent Parkinson’s Disease Risk by Polygenic Hazard Score The practical takeaway is that PRS may be most useful as a screening tool earlier in life, when traditional risk factors haven’t yet developed and genetic predisposition accounts for a larger share of who gets sick.
When You Also Carry a High-Risk Gene Mutation
PRS and single-gene (monogenic) testing are sometimes presented as separate tracks, but they interact in important ways. Even among people who carry a known high-risk mutation, such as a BRCA1 variant for breast cancer or a familial hypercholesterolemia variant for heart disease, the polygenic background can dramatically modify the actual risk of developing the disease. A study of carriers of monogenic risk variants for coronary artery disease, breast cancer, and colon cancer found that the probability of disease by age 75 ranged from 17% to 78% for coronary artery disease, 13% to 76% for breast cancer, and 11% to 80% for colon cancer, depending on the individual’s polygenic background.17Nature Communications. Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions
That range is enormous. Two people carrying the exact same BRCA1 mutation can have vastly different lifetime risks based on the cumulative effect of their other genetic variants. Research on specific BRCA1 pathogenic variants confirmed that a PRS model could meaningfully predict breast cancer risk in carriers, helping to distinguish higher-risk from lower-risk carriers within the same mutation group.18PubMed Central. Polygenic Risk Score Predicts Modified Risk in BRCA1 Pathogenic Variant c.4035del and c.5266dup Carriers in Breast Cancer Patients This has real clinical implications: a mutation carrier whose PRS places them at the low end of polygenic risk might make different decisions about preventive surgery or screening intensity than one at the high end.
Not All High Scores Are Created Equal
A high PRS for a given disease does not always mean the same thing for every person who carries one. Recent work on coronary artery disease has shown that the genetic risk driving a high score can come from very different biological pathways. Some people’s elevated risk is driven primarily by variants linked to lipid metabolism, while others accumulate their risk through variants connected to blood pressure, inflammation, obesity, or diabetes-related pathways. Researchers have developed methods to decompose a single coronary artery disease PRS into pathway-specific sub-scores, and they found that individuals in different subgroups had distinct clinical profiles matching their genetic burden: people in the lipid-related subgroup had higher cholesterol-related measures, while those in the obesity subgroup had higher BMI and body fat.19PLoS Computational Biology. Robust pleiotropy-decomposed polygenic scores identify distinct contributions to elevated coronary artery disease polygenic risk
This is clinically relevant because it suggests that two people with the same high PRS for heart disease may benefit from different prevention strategies. One might need aggressive lipid-lowering therapy while another might benefit more from blood pressure management or weight loss interventions. The PRS of the future may not just tell you your overall risk but help pinpoint which biological lever matters most for you.
Genes, Environment, and the Stress Connection
A PRS captures genetic predisposition, but whether that predisposition translates into actual disease depends heavily on what happens in your life. The study of gene-environment interactions using PRS has found partial support for the idea that people with higher genetic liability to depression are more vulnerable to the harmful effects of stressful life events. Some large-scale studies report significant interactions, while others find that genes and environment act independently without amplifying each other. Where interactions are found, the effect sizes tend to be modest.20PubMed Central. Polygenic scores in the study of gene-environment interplay and stress-related psychopathology
This matters for how you should interpret a PRS result. A high genetic risk for depression does not mean depression is inevitable. It means that under the right (or wrong) environmental conditions, you may be somewhat more susceptible. It also means that if you manage stress effectively, your elevated genetic risk may never fully express itself. The difficulty is that current PRS cannot tell you which specific environmental factors will tip the balance for any given individual.
Direct-to-Consumer Testing and What You Get
Several companies now offer PRS as part of consumer genetic testing packages. These services typically genotype a subset of your DNA using a saliva sample and calculate scores for conditions like heart disease, diabetes, or certain cancers. A validation study of cardiometabolic PRS built from direct-to-consumer genetic data reported an area under the curve of 0.68, which is comparable to models built from larger clinical datasets.21PubMed Central. Validating and automating learning of cardiometabolic polygenic risk scores from direct-to-consumer genetic and phenotypic data: implications for scaling precision health research That performance level is real but modest: it is better than a coin flip but far from diagnostic precision.
How PRS results are communicated to consumers also varies widely. A review of polygenic risk score reports found that the presentation differs across companies and studies, including icon arrays, bell curves, absolute risk numbers, and relative risk comparisons. Research supported using absolute risk figures rather than relative risk, and avoiding color schemes that stigmatize or cause unnecessary alarm.22PubMed. The development and evaluation of polygenic risk score reports: A systematized review of the literature A relative risk of “two times average” sounds alarming until you learn that your baseline risk was 1%, making your adjusted risk 2%, which is still quite low. Without proper context, PRS results can easily mislead.
Embryo Selection and the Designer Baby Debate
One of the more controversial applications of PRS is in preimplantation genetic testing during IVF, where embryos are screened and selected partly on the basis of polygenic scores for diseases like heart disease, diabetes, or even traits like height. A comprehensive review of this practice found that while theoretical models suggest some reduction in disease risk, the realized benefits may be considerably smaller than projected, largely because couples produce a limited number of embryos and the accuracy of the risk estimates remains uncertain.23PubMed Central. Screening embryos for polygenic disease risk: a review of epidemiological, clinical, and ethical considerations
The ethical concerns are substantial. The same review catalogued harms including patients undergoing IVF solely for embryo selection when they have no fertility issues, possible reductions in IVF success rates from discarding otherwise viable embryos, and inadequate genetic counseling. At a societal level, worries include increasing demand for trait selection beyond disease prevention, overemphasis on genetics as destiny, unequal access to the technology, and the familiar problem of lower accuracy in non-European populations. For people who attribute significant moral status to embryos, the additional discarding of viable embryos raises a separate set of concerns.24Human Reproduction Update. Screening embryos for polygenic disease risk: a review of epidemiological, clinical, and ethical considerations – Section: Possible harms to PES patients, their offspring, and society
Who Pays and Whether It Is Worth It
For PRS to move from research curiosity to routine clinical tool, it has to be cost-effective. Several health-economic analyses suggest it can be, at least for cardiovascular disease. A modeling study of PRS-guided statin therapy in a workplace wellness program found that incorporating PRS lowered employer costs while slightly improving employee quality-adjusted life years compared to standard wellness programs and no program at all.25PubMed Central. Cost-effectiveness analysis of implementing polygenic risk score in a workplace cardiovascular disease prevention program A system dynamics model evaluating PRS use in primary prevention of coronary artery disease found the cost per quality-adjusted life year gained was well below $50,000 across multiple use scenarios, with broader use yielding greater cost-effectiveness.26American Journal of Preventive Cardiology. Health economic analysis of polygenic risk score use in primary prevention of coronary artery disease – A system dynamics model
The cost-effectiveness picture is less clear for other conditions. An analysis of population-wide genomic screening that combined Lynch syndrome testing with PRS for colorectal cancer found the incremental cost-effectiveness ratio was about $124,000 per quality-adjusted life year, which falls below the $150,000 willingness-to-pay threshold used in the study but is considerably more expensive than the cardiovascular applications.27PubMed Central. Cost-effectiveness of population-wide genomic screening for Lynch Syndrome and polygenic risk scores to inform colorectal cancer screening These numbers will shift as genotyping costs continue to fall and PRS accuracy improves, but for now, the economic case is strongest where the score is paired with a well-established, inexpensive intervention like statin therapy.
Legal Protections and the Gaps in Them
If you get a PRS through a clinical or consumer test, you might wonder whether it could be used against you. In the United States, the Genetic Information Nondiscrimination Act (GINA) prohibits health insurers from using genetic information in coverage decisions and bars employers from using it in hiring, firing, or promotion. Genetic information under GINA includes your genetic test results, the genetic tests of family members, and the manifestation of disease in your family.28PubMed Central. Polygenic disease risk scoring and genetic non-discrimination
But GINA has well-known gaps. It does not apply to life insurance, disability insurance, or long-term care insurance. And the legal landscape for PRS specifically is murkier than for traditional genetic tests, because PRS are built from common variants rather than rare pathogenic mutations, and existing legal frameworks were not designed with that distinction in mind. Some legal scholars have raised concerns that protections may not clearly extend to polygenic scores, particularly when those scores are used to make behavioral or sociological inferences rather than strictly medical ones.29PubMed Central. The Legal Uncertainties of Sociogenomic Polygenic Scores If PRS become routine in healthcare, these regulatory gaps will need to be addressed before the technology outpaces the law.